Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J's Gamma First PMA Submission For Vascular Brachytherapy System

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson's premarket approval application for the Gamma brachytherapy system for treatment of coronary artery disease has been granted expedited review by FDA and potentially could be approved by year-end or early 2000, the company indicated following its announcement July 14 of the PMA filing.

You may also be interested in...



Gamma System Late Thrombosis Concern Mitigated By Outside Data - Cordis

Johnson & Johnson Cordis is hoping for a chance to make its case before FDA's Circulatory System Devices Panel that FDA should consider data neither generated by the company nor included in the premarket approval application for its Gamma brachytherapy system for treatment of coronary artery restenosis.

Gamma System Late Thrombosis Concern Mitigated By Outside Data - Cordis

Johnson & Johnson Cordis is hoping for a chance to make its case before FDA's Circulatory System Devices Panel that FDA should consider data neither generated by the company nor included in the premarket approval application for its Gamma brachytherapy system for treatment of coronary artery restenosis.

J&J's Gamma Brachytherapy System Effectively Reduces Restenosis - TCT

Physicians treating in-stent restenosis with intravascular brachytherapy should avoid placing new stents at the time of radiation, Paul Teirstein, MD, Scripps Clinic, La Jolla, California cautioned in a Sept. 23 release announcing the results of the Johnson & Johnson GAMMA I trial.

Related Content

UsernamePublicRestriction

Register

MT012056

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel